Skip to main content
Figure 4 | Journal of Translational Medicine

Figure 4

From: The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis

Figure 4

Expression of CX3CR1 in the three circulating monocyte subsets examined in patients with RA at baseline and over MTX treatment. Fluorescence intensities (MFI) of CX3CR1 in circulating CD14+highCD16 (panel A), CD14+highCD16+ (panel B) and CD14+lowCD16+ monocytes (panel C) of non-responders (■)and responders () at baseline and after 3 and 6 months of MTX treatment, and in healthy controls (), are shown as means ± SEM. Panel D is a histogram of CX3CR1 for circulating CD14+highCD16- monocytes from a representative responder and non-responder at 6 months of treatment and their respective isotype controls. *Significant difference between patients and healthy controls. Significant difference between non-responders and responders. Significant difference between baseline and 6 month values.

Back to article page